Efgartigimod alfa for the treatment of primary immune thrombocytopenia
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Most patients with ITP have antiplatelet antibodies of the immunoglobulin G (IgG) subtype which through interaction with platelet and megakaryocyte glycoproteins result in increased p...
Main Author: | Catherine Broome |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-05-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/20406207231172831 |
Similar Items
-
S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
by: Monica Carpenedo, et al.
Published: (2023-08-01) -
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
by: Paul C. Langley
Published: (2021-10-01) -
The tale and trials of Efgartigimod: a newly FDA approved drug for the treatment of Myasthenia gravis
by: Kashaf Waqar, et al.
Published: (2022-10-01) -
Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
by: Sandra E. Reznik, et al.
Published: (2023-06-01) -
PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
by: P. Knoebl, et al.
Published: (2022-06-01)